Lancashire and South Cumbria
Formulary
Formulary
14 Immunological products and vaccines
This chapter does not contain details of vaccines that are otherwise listed in ‘Immunisation against infectious disease’ (the “Green Book”). Please consult this reference for details of vaccines and related products. |
14-04 Botulism antitoxin
| Botulism antitoxin |
|
Formulary
|
|
 MHRA: Botulism: clinical and public health management |
|
All patients should be tested for sensitivity (diluting the antitoxin if history of allergy).Links
- DH Vaccine Update re: Change of HPV vaccine from Cervarix® to Gardasil® in September 2012
Green Book (pg 5/6): Change from 3 dose to 2 dose schedule from September 2014 for routine vaccination of 11 - 13 year olds- HPA: Guidelines on managing rabies post-exposure prophylaxis
- Influenza vaccine and porcine gelatine (NHS Public Health)
- LSCMMG: Inflammatory Bowel Disease: High Cost Drugs Commissioning Pathway
- LSCMMG: Primary Care Constipation Guidelines
- MHRA Drug Safety Update April 2016: Live attenuated vaccines: avoid use in those who are clinically immunosuppressed
- MHRA Drug Safety Update April 2019: Yellow fever vaccine (Stamaril) and fatal adverse reactions: extreme caution needed in people who may be immunosuppressed and those 60 years and older
- MHRA Drug Safety Update Dec 2019: Yellow fever vaccine: stronger precautions in people with weakened immunity and in those aged 60 years or older
- MHRA drug Safety Update November 2021: Yellow fever vaccine (Stamaril): new pre-vaccination checklist
- MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- MHRA: Botulism: clinical and public health management
- NICE CG147: Diverticular disease: diagnosis and management
- NICE CG184 Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management
- NICE CG61: Irritable bowel syndrome in adults: diagnosis and management
- NICE NG1: Gastro-oesophageal reflux disease: recognition, diagnosis and management in children and young people
- NICE TA601: Bezlotoxumab for preventing recurrent Clostridium difficile infection (terminated appraisal)
- Public Health England: Changes to the meningococcal C conjugate (MenC) vaccine schedule 2013 to 2014: advice for healthcare professionals
- UKMI Q&A: Is Yellow Fever vaccine safe whilst breastfeeding